Summary
The role of age, gender, smoking habits and concomitant drug treatment, and type and dose of angiotensin converting enzyme (ACE) inhibitor as prognostic factors for the development of cough during ACE inhibition was investigated in a group of 1591 patients. In 117 of these patients cough was identified as drug related. Logistic regression confirmed that females, nonsmokers and patients treated with enalapril are at greater risk of developing cough. On the other hand, our data provided no evidence for a prognostic role of higher doses of the ACE inhibitor or of concomitant drug treatment; in particular, the use of β-adrenoceptor antagonists was not associated with a higher incidence of cough.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Berkin KE. Respiratory effects of angiotensin converting enzyme inhibition. European Respiration Journal 2: 198–201, 1989
Berkin KE, Ball SG. Cough and angiotensin converting enzyme inhibition. ACE Report 48: 1–7, 1988
Chalmers D, Dombey SL, Lawson DH. Post-marketing surveillance of captopril (for hypertension): a preliminary report. British Journal of Clinical Pharmacology 24: 343–349, 1987
Coulter DM, Edwards IR. Cough associated with captopril and enalapril. British Medical Journal 294: 1521–1523, 1987
Edwards IR, Coulter DM, Beasley DMG, Mackintosh D. Captopril: 4 years of post-marketing surveillance of all patients in New Zealand. British Journal of Clinical Pharmacology 23: 529–536, 1987
Gibson GR. Enalapril-induced cough. Archives of Internal Medicine 149: 2701–2703, 1989
Goldszer RC, Lilly LS, Solomon HS. Prevalence of cough during angiotensin-converting enzyme inhibitor therapy. American Journal of Medicine 85: 887, 1988
Karpman L. Cough from ACE inhibitors. American Heart Journal 116: 1658, 1988
Lilienfeld AM. Foundations of epidemiology, pp. 194–204, Oxford University Press, New York, 1976
Morice AH, Brown MJ, Higenbottam T. Cough associated with angiotensin converting enzyme inhibition. Journal of Cardiovascular Pharmacology 13 (Suppl. 3): S59–S62, 1989
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, et al. A method for estimating the probability of adverse reactions. Clinical Pharmacology and Therapeutics 30: 239–245, 1981
Puolijoki HJ, Nieminen M, Moilanen E, Siitonen L, Lahdensuo A, et al. Cough induced by enalapril but not captopril. European Respiration Journal 2: 289–291, 1989a
Puolijoki HJ, Nieminen MM, Siitonen LO, Lahdensuo AHS, Reinikainen PMO. Is simultaneous β-blocker therapy a risk factor for enalapril-induced cough? Respiration 55: 127–128, 1989b
Strocchi E, Valtancoli G, Ambrosioni E. The incidence of cough during treatment with angiotensin converting enzyme inhibitors. Journal of Hypertension 7 (Suppl. 6): S308–S309, 1989
Town GI, Hallwright GP, Maling TJB, O’Donnell TV. Angiotensin converting enzyme inhibitors and cough. New Zealand Journal of Medicine 100: 161–163, 1987
Uzubalis RI, Frewin DB, Bushell MK, McEvoy RD. The effect of angiotensin converting enzyme inhibitors (ACE-I) and selective β1 -antagonists on bronchial reactivity and the cough reflex in man. European Journal of Clinical Pharmacology 37: 467–470, 1989
Yeo WW, Ramsay LE. Persistent dry cough with enalapril: incidence depends on method used. Journal of Human Hypertension 4: 517–520, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Strocchi, E., Malini, P.L., Valtancoli, G. et al. Cough during Treatment with Angiotensin Converting Enzyme Inhibitors. Drug Invest 4, 69–72 (1992). https://doi.org/10.1007/BF03258383
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03258383